The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation

被引:0
|
作者
Rossi, Esther Diana [1 ]
Bizzarro, Tommaso [1 ]
Granja, Sara [2 ,3 ]
Martini, Maurizio [1 ]
Capodimonti, Sara [1 ]
Luca, Emilia [1 ]
Fadda, Guido [1 ]
Lombardi, Celestino Pio [4 ]
Pontecorvi, Alfredo [5 ]
Larocca, Luigi Maria [1 ]
Baltazar, Fatima [2 ,3 ]
Schmitt, Fernando [6 ,7 ,8 ]
机构
[1] Catholic Univ Sacred Heart Rome, Div Anat Pathol, Milan, Italy
[2] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal
[3] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
[4] Univ Cattolica Sacro Cuore, Div Endocrine Surg, Milan, Italy
[5] Univ Cattolica Sacro Cuore, Div Endocrinol, Milan, Italy
[6] Med Fac Univ, Porto, Portugal
[7] Inst Pathol Mol Immunol Porto, Porto, Portugal
[8] Lab Natl Sante Luxembourg, Luxembourg, Luxembourg
关键词
Liquid-based cytology; Thyroid lesions; PTC; Plump cells; MCTs; BRAF(V600E) mutation; LIQUID-BASED CYTOLOGY; ASPIRATION BIOPSIES; MALIGNANT-MELANOMA; PROGNOSTIC VALUE; BRAF(V600E); CANCER; CELLS; IMMUNOHISTOCHEMISTRY; IMPACT; CD147;
D O I
10.1007/s12020-016-1044-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BRAF (V600E) mutation, usually performed by DNA techniques, is one of the most common diagnostic markers in papillary thyroid carcinoma. Few papers have demonstrated that plump cells (eosinophilic cytoplasms and papillary thyroid carcinoma nuclei) and peculiar sickle-shaped nuclei represent morphological features of BRAF (V600E) on papillary thyroid carcinomas. These features seem to be linked to glycolytic phenotype whereby monocarboxylate transporters 1-4 are hypothesized to have a dominant role as lactate transporters. We investigated the association between these morphological features and monocarboxylate transporters 1 and 4 in 48 cyto-histological samples diagnosed as "positive for malignancy-favoring papillary thyroid carcinoma". These cases were processed with liquid-based cytology and underwent BRAF (V600E) mutational analysis (pyrosequencing) on liquid-based cytology and monocarboxylate transporters immunostaining on histology. The expression of monocarboxylate transporter 1, monocarboxylate transporter 4, glucose trasporter-1 and carbonic anhidrase were scored semi-quantitatively with expression from 0 to 3+ (strong positivity). The 33 mutated and 15 wild type cases showed 100 % cyto-histological concordance. The cytological evaluation revealed plump cells and sickle nuclear shape in 100 % mutated cases. Monocarboxylate transporter 1 yielded 76 % positivity in the mutated cases especially in both the plump cells and sickle-shaped nuclei, whereas the wild types showed 13.3 % positive monocarboxylate transporter 1 (p = 0.00013). Monocarboxylate transporter 4 resulted in 100 % positivity in mutated and 40 % in wild types (p < 0.005). Furthermore, 20 % of the wild types showed weak monocarboxylate transporter 1 nuclear expression associated to a less aggressive behavior. The analysis of glucose trasporter-1 and carbonic anhidrase did not highlight any statistical significance (p > 0.05). This is the first report analyzing the association between monocarboxylate transporter expression and the morphological features of BRAF (V600E) mutated papillary thyroid carcinomas suggesting the possible involvement of lactate in the morphological features.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [41] A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
    Pancer, Jill
    Mitmaker, Elliot
    Ajise, Oluyomi
    Tabah, Roger
    How, Jacques
    ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2019,
  • [42] ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?
    Lai, Hon-Fan
    Hang, Jen-Fan
    Chen, Jui-Yu
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (06) : 3974 - 3975
  • [43] Is There a Clinical or Diagnostic Utility for BRAF V600E Mutation in Thyroid Lesions?
    Deng, C.
    Liu, Y. L.
    Knezetic, J.
    Gatalica, Z.
    LABORATORY INVESTIGATION, 2009, 89 : 338A - 338A
  • [44] EGFR Expression and V600E BRAF Mutations Influence Disease Progression in Thyroid Carcinoma
    Fisher, K. E.
    Hill, C. E.
    Foulks, C.
    Weber, C. J.
    Sharma, J.
    Cohen, C.
    LABORATORY INVESTIGATION, 2012, 92 : 143A - 144A
  • [45] In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation
    Nasirden, Almira
    Saito, Tsuyoshi
    Fukumura, Yuki
    Hara, Kieko
    Akaike, Keisuke
    Kurisaki-Arakawa, Aiko
    Asahina, Miki
    Yamashita, Atsushi
    Tomomasa, Ran
    Hayashi, Takuo
    Arakawa, Atsushi
    Yao, Takashi
    VIRCHOWS ARCHIV, 2016, 469 (06) : 687 - 696
  • [46] Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status
    Walts, Ann E.
    Mirocha, James M.
    Bose, Shikha
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (10) : 1749 - 1756
  • [47] EGFR Expression and V600E BRAF Mutations Influence Disease Progression in Thyroid Carcinoma
    Fisher, K. E.
    Hill, C. E.
    Foulks, C.
    Weber, C. J.
    Sharma, J.
    Cohen, C.
    MODERN PATHOLOGY, 2012, 25 : 143A - 144A
  • [48] Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status
    Ann E. Walts
    James M. Mirocha
    Shikha Bose
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1749 - 1756
  • [49] Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma
    Sun, Jian
    Zhang, Jing
    Lu, Junliang
    Gao, Jie
    Lu, Tao
    Ren, Xinyu
    Duan, Huanli
    Liang, Zhiyong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 15072 - 15078
  • [50] Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
    Gandolfi, Greta
    Sancisi, Valentina
    Piana, Simonetta
    Ciarrocchi, Alessia
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (05) : 1001 - 1011